Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis Meeting Abstract
| Authors: | Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; Lucchesi, A.; Kuykendall, A. T.; Mesa, R. A.; Kiladjian, J. J.; Talpaz, M.; Harris, M.; Wu, M.; Brown, B.; Harrison, C.; Mascarenhas, J. |
| Abstract Title: | Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401572 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.6502 |
| Notes: | Meeting Abstract: 6502 -- Source: Wos |
